Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

April 13, 2021
Andrew Coveler, MD

Partner | Cancer Centers | <b>SCCA</b>

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

Andrew Coveler, MD, director, Pancreatic Cancer Specialty Clinic, Seattle Cancer Care Alliance, associate professor, Medical Oncology, University of Washington School of Medicine, physician, UW Medicine, and associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer (mCRC).

During the 2021 Gastrointestinal Cancers Symposium, findings from the phase 1b NuTide:302 study of NUC-3373 in combination with standard therapies in patients with mCRC were presented. The targeted inhibitor of thymidylate synthase demonstrated encouraging efficacy in this patient population.

Regarding safety, NUC-3373 demonstrated similar toxicities to 5-fluorouracil, such as diarrhea, says Coveler. Nausea was common with NUC-3373, but was manageable with additional medications, explains Coveler. Mouth sores, fatigue, and anemia were also observed with NUC-3373, but white blood cell counts appeared to remain relatively stable with the agent, concludes Coveler.